Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
PRAX
PRAXIS PRECISION MEDICINES, INC.
NASDAQ
$312.90
▼ DOWN 5.34% (-17.65)

KEY STATISTICS

Market Cap$8.73 B
52w High$392.70
52w Low$41.77
Dividend Yield—
Frequency—
P/E-24.20
Volume204.33K
Shares Out.27.88M

COMPANY

LEADERSHIP

Marcio Silva De'Souza
CHIEF EXECUTIVE
Marcio Silva De'Souza

COMPENSATION 2026

Salary$659,200
Stock Awards$2,368,125
Incentive Plan Pay$1,483,200
All Other Comp.$506,998
Total$8,708,648

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 16, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
168

PRICE TARGET

Target High$1201.00
Target Low$162.00
Target Median$575.00
Target Consensus$603.83

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$130.77K
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2023-11-29Reverse1:15

PRICE

$312.90 ▼ DOWN 5.34% (−$17.65)
OVERLAYS
$315$323$3309:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM312.90

About Praxis Precision Medicines, Inc.

https://www.praxismedicines.com ↗

Praxis Precision Medicines, a Boston-based clinical-stage biopharma, develops CNS disorder therapies like PRAX-114 and PRAX-944, targeting depression, tremor, epilepsy, and related conditions through innovative drug candidates and collaborations.

INDUSTRY

Biotechnology

A PRODUCT PRAXIS PRECISION MEDICINES, INC. IS KNOWN FOR

Ulixacaltamide
Ulixacaltamide

Ulixacaltamide is an investigational oral drug for essential tremor, showing positive Phase 3 results, FDA Breakthrough Therapy Designation, and a submitted NDA as Praxis' most advanced pipeline candidate.

COMPETITORS

COMPETITOR
AXSM COMPARE
NBIX COMPARE
RAPP COMPARE
XENE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
188
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.01% · 888.2K
IWM
0.27% · 657.5K
XBI
1.35% · 433.1K
SCHA
0.19% · 125.4K
FESM
0.31% · 59.0K
QMOM
1.92% · 24.5K
TMSL
0.27% · 24.1K
XRS2.DE
0.27% · 22.3K
LABU
1.02% · 15.8K
DFAS
0.03% · 13.0K
RSSL
0.27% · 12.1K
SBIO.MI
0.63% · 9.3K
JHMM
0.05% · 8.2K
USVM
0.15% · 7.9K
JSML
0.69% · 7.4K
GSC
0.89% · 7.3K
MSSM
0.30% · 6.3K
BBSC
0.29% · 6.2K
BKMC
0.22% · 4.3K
LF
LFSC
0.93% · 3.5K
IQSM
0.31% · 3.5K
FNY
0.16% · 2.8K
SEIS
0.15% · 2.6K
AVUS
0.00% · 1.6K
203780.KS
0.63% · 1.4K
MEDI
0.96% · 1.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
81.78%
HOLDERS
373
TOP 12 OF 373 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
3.2M sh · $954.83M
Orbis Allan Gray Ltd
2.5M sh · $796.61M
Adage Capital Partners Gp, L.L.C.
2.4M sh · $125.83M
Blackrock, Inc.
2.3M sh · $749.07M
Fmr LLC
2.3M sh · $775.68M
Perceptive Advisors LLC
2.0M sh · $681.63M
Baker Bros. Advisors LP
1.8M sh · $586.95M
Point72 Asset Management, L.P.
1.5M sh · $79.29M
Vanguard Group Inc
1.5M sh · $430.6M
Blackrock Inc.
1.3M sh · $53.52M
State Street Corp
1.0M sh · $343.66M
Price T Rowe Associates Inc /Md/
1.0M sh · $53.19M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity5
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Ray Cisneros
Gilbert Ray Cisneros
Purchase
2026-07-30

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Souza Marcio
Sale · 20.5K shares
2026-07-08
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Souza Marcio
Sale · 2.6K shares
2026-07-08
★
DIRECTOR
DeSimone Jill
Sale · 2.9K shares
2026-06-24
★
DIRECTOR
DeSimone Jill
Sale · 120 shares
2026-06-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 10
OUTPERFORM 3
EQUAL WEIGHT 1
UNDERPERFORM 1
OVERWEIGHT 1
16 GRADES IN THE LAST 12 MONTHS
Goldman Sachs BUY Wells Fargo EQUAL WEIGHT RBC Capital OUTPERFORM Needham BUY BTIG BUY HC Wainwright & Co. BUY Deutsche Bank BUY Baird OUTPERFORM

SECTORS PEERS

PEERPRICE
KYMR$113.26COMPARE
IMVT$36.60COMPARE
XENE$56.57COMPARE
LGND$272.35COMPARE
ACAD$26.87COMPARE
VKTX$29.98COMPARE